MediGO is Latest Recipient of National Kidney Foundation Innovation Fund Investment

Innovative technology to enable digital transformation of the kidney transplant supply chain and improve fairness and transparency

New York, December 20, 2022 /PRNewswire/ — NKF’s philanthropic impact investment program, the National Kidney Foundation (NKF) Innovation Fund, has invested in MediGO Inc., a first-of-its-kind healthcare supply chain technology company focused on equity improvement. Made the latest investment. , access and transparency in the organ donation and transplant industry. MediGO is digitally transforming kidney donation and transplant surgery to increase access to life-saving organs and tissues. NKF funding will support MediGO’s development, implementation and overhaul of its renal transplant supply chain through technological advances.

The supply chain that fuels the organ donation and transplant industry is a complex ecosystem in which medical teams, support staff, pilots, couriers, and families work together to save lives from precious organs. Supply chains consist of many steps and have historically lacked end-to-end visibility, agility and fairness. Life-saving organs have been tracked with a system of text, phone, and paper trails leading to system waste and inefficiency.

Its inefficiency and lack of transparency can lead to a lack of trust among stakeholders, a leading reason for organ donation refusals. The key to building this confidence and trust is improving the transparency of the organ donation process.

“Equity in the organ donation system cannot be achieved without instilling trust and trust among stakeholders,” he said. Kevin Longino, CEO of NKF and a kidney transplant recipient. “Right now, there’s no real transparency. It’s not as easy to track a holiday gift as it is to track a donated kidney en route to a life-saving transplant.”

“We launched the NKF Innovation Fund because the kidney care situation in this country is fundamentally broken,” he added. “The work MediGO is doing has the potential to completely overhaul an important part of the landscape and dramatically improve the transparency of the organ donation process. Giving to this company is exactly why we started this fund.”

MediGO’s Donation and Transplant Supply Chain software solution gives Organ Procurement Organizations (OPOs) and Transplant Center teams the ability to integrate distributed stakeholders, coordinate resources and make critical decisions. This improves quality and instills trust among all stakeholders in the organ donation and transplantation system. MediGO’s newest product, Organ TeamLink™, gives OPOs the ability to efficiently respond to donor referrals and set them up for success.

“From the beginning, our vision for MediGO has been to revolutionize the organ donation and transplant process. It brings a collaborative and innovative approach to solving logistics challenges.” Scott Plank, co-founder and CEO of MediGO. “Currently, kidneys make up over 90% of the organs tracked on the MediGO platform.As a result, this partnership makes strategic sense for us.We appreciate the experience of our users and industry partners. We are very focused on listening and this results in a better platform and a stronger impact on the overall donation and transplant network. Helping this community save time and money and improve the quality of the gift of life. It’s a privilege to help make a difference. Together, we can save more lives.

MediGO’s Revolutionary Healthcare Supply Chain Technology Digitally Transforms the U.S. Organ Donation and Transplant System to Improve Equity and Equity, Reduce Donated Organ Waste, and Save More Lives increase.Edison Award and first company With disruptive technology powered by proprietary algorithms and machine learning, MediGO provides the most actionable data available in the donation and transplant industry. For more information on MediGO, visit

Launched in 2021, the NKF Innovation Fund is working to accelerate the funding, development and commercialization of much-needed and deserving treatments for kidney disease patients. The fund invests in early to mid-stage companies developing innovative, patient-centered renal therapies. The long-term goal of the NKF Innovation Fund is to prevent kidney disease, eliminate waiting lists for transplants and provide better and safer treatments for dialysis patients so they can live fuller and more productive lives. For more information on the NKF Innovation Fund, please visit

For more information about kidney disease and how to maintain optimal kidney health, visit our Kidneys site./.

About kidney disease

of usa, an estimated 37 million adults have kidney disease, also known as chronic kidney disease, and about 90% are unaware they have it. One in three of her American adults is at risk of chronic kidney disease. Risk factors for kidney disease include diabetes, hypertension, heart disease, and obesity., and family history. People of African American, Hispanic, Native American, Asian, or Pacific Islander descent are at increased risk of developing the disease. African Americans are about four times more likely to have kidney failure than white Americans. A Hispanic is 1.3 times more likely than a non-Hispanic to have kidney failure.

About the National Kidney Foundation

The National Kidney Foundation (NKF) is the largest and most comprehensive organization., A longstanding patient-focused organization dedicated to awareness and prevention, For more information on NKF, please visit

Source National Kidney Foundation

Source link

Leave a Reply